Sponsors (2)
Establishes an NIH X‑Labs Initiative to award multi‑year institutional grants (XL01–XL04) for breakthrough biomedical research with defined per‑award annual ranges.
Official title: To direct the Director of the National Institutes of Health to carry out a program, to be known as the "X-Labs Initiative", to support breakthrough biomedical research at innovative research institutions, and for other purposes.
Introduced December 10, 2025 by Josh Harder · Last progress December 10, 2025
The bill creates large, predictable, flexible funding pathways (including intermediary‑channeled and planning awards) to support high‑risk, high‑reward biomedical research, but does so at the cost of concentrating federal R&D dollars, restricting recipients' access to other grants, increasing NIH discretion, and adding administrative burdens that could reduce funding flexibility and oversight.
Scientists, research institutions, and universities receive predictable, large multi‑year funding (7‑year awards of $5M–$50M) that enables ambitious, high‑risk biomedical projects that are difficult to support through standard grants.
Nonprofit intermediaries and early‑stage U.S. research teams gain new channels for funding unconventional, high‑risk projects, making it likelier that breakthrough discoveries move forward outside standard NIH pathways.
Scientists, nascent institutions, and nonprofits can access smaller planning awards (XL04 of $1M–$5M for 1–3 years), lowering barriers to forming new scientific institutions and encouraging institutional diversity and innovation.
Researchers and universities risk a concentration of federal R&D dollars in a limited set of large, multi‑year awards, which could reduce funding available for traditional investigator‑initiated grants and shrink competitive diversity.
Recipients of XL01–XL03 awards are barred from competing for other federal research grants during their award periods, limiting access to complementary funding and reducing research funding flexibility for affected investigators and institutions.
The program grants NIH broad discretion over eligibility, selection, and use of other‑transaction authorities, which could weaken standard peer‑review safeguards, create procurement or oversight risks, and reduce accountability to taxpayers.
Based on analysis of 2 sections of legislative text.
Creates a new NIH program called the X‑Labs Initiative to provide multi‑year, large institutional awards for breakthrough biomedical research and to support formation of new research institutions. It establishes four award categories (XL01–XL04) with multi‑year funding floors and ceilings, rules for regranting (for XL03), renewal conditions, and reporting requirements, but does not set overall funding levels, eligibility details, or application procedures.